TxCell clinical trials
Acquired by Sangamo Therapeutics, Oct 1, 2018 · source ↗
The registry lists 1 studies whose lead sponsor is TxCell. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 25, 2017.
Before and after it joined Sangamo Therapeutics
- First submitted before TxCell became part of Sangamo Therapeutics
- 1
- First submitted after TxCell became part of Sangamo Therapeutics
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- TxCell1 study
Something wrong with this grouping? Tell us on the Sangamo Therapeutics page.
Studies
Recruiting first, then most recently updated. Showing 1 of 1. All Sangamo Therapeutics studies →
- Study Evaluating Ovasave, an Autologous Cell Therapy, in Patients With Active Crohn's DiseaseTerminatedNCT02327221Phase 2
Sponsor listed in the registry: TxCell · First submitted before TxCell became part of Sangamo Therapeutics